These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 19182372

  • 1. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
    Higuchi T, Nakamura T, Kakutani H, Ishii H.
    Biol Pharm Bull; 2009 Feb; 32(2):179-85. PubMed ID: 19182372
    [Abstract] [Full Text] [Related]

  • 2. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
    Bazzi ZA, Lanoue D, El-Youssef M, Romagnuolo R, Tubman J, Cavallo-Medved D, Porter LA, Boffa MB.
    BMC Cancer; 2016 May 24; 16():328. PubMed ID: 27221823
    [Abstract] [Full Text] [Related]

  • 3. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO.
    J Biol Chem; 2011 Jan 07; 286(1):502-10. PubMed ID: 21041299
    [Abstract] [Full Text] [Related]

  • 4. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
    van Moorsel MVA, Poolen GC, Koekman CA, Verhoef S, de Maat S, Barendrecht A, van Kleef ND, Meijers JCM, Schiffelers RM, Maas C, Urbanus RT.
    J Thromb Haemost; 2022 May 07; 20(5):1213-1222. PubMed ID: 35170225
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
    Binette TM, Taylor FB, Peer G, Bajzar L.
    Blood; 2007 Nov 01; 110(9):3168-75. PubMed ID: 17644733
    [Abstract] [Full Text] [Related]

  • 6. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ.
    J Thromb Haemost; 2016 Aug 01; 14(8):1629-38. PubMed ID: 27279497
    [Abstract] [Full Text] [Related]

  • 7. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor.
    Bajzar L, Nesheim M, Morser J, Tracy PB.
    J Biol Chem; 1998 Jan 30; 273(5):2792-8. PubMed ID: 9446587
    [Abstract] [Full Text] [Related]

  • 8. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
    Semeraro F, Ammollo CT, Gils A, Declerck PJ, Colucci M.
    J Thromb Haemost; 2013 Dec 30; 11(12):2137-47. PubMed ID: 24134522
    [Abstract] [Full Text] [Related]

  • 9. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
    Plug T, Marquart JA, Marx PF, Meijers JC.
    J Thromb Haemost; 2015 Nov 30; 13(11):2093-101. PubMed ID: 26341360
    [Abstract] [Full Text] [Related]

  • 10. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.
    Foley JH, Nesheim ME.
    J Thromb Haemost; 2009 Mar 30; 7(3):453-9. PubMed ID: 19087221
    [Abstract] [Full Text] [Related]

  • 11. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin.
    Marar TT, Boffa MB.
    J Thromb Haemost; 2016 Apr 30; 14(4):772-83. PubMed ID: 26816270
    [Abstract] [Full Text] [Related]

  • 12. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
    Wu C, Stafford AR, Fredenburgh JC, Weitz JI, Gils A, Declerck PJ, Kim PY.
    Thromb Haemost; 2017 Jul 26; 117(8):1509-1517. PubMed ID: 28640323
    [Abstract] [Full Text] [Related]

  • 13. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.
    Bazzi ZA, Balun J, Cavallo-Medved D, Porter LA, Boffa MB.
    Clin Exp Metastasis; 2017 Feb 26; 34(2):155-169. PubMed ID: 28124276
    [Abstract] [Full Text] [Related]

  • 14. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
    Marx PF, Havik SR, Marquart JA, Bouma BN, Meijers JC.
    J Biol Chem; 2004 Feb 20; 279(8):6620-8. PubMed ID: 14660622
    [Abstract] [Full Text] [Related]

  • 15. The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.
    Wu C, Kim PY, Manuel R, Seto M, Whitlow M, Nagashima M, Morser J, Gils A, Declerck P, Nesheim ME.
    J Biol Chem; 2009 Mar 13; 284(11):7059-67. PubMed ID: 19074424
    [Abstract] [Full Text] [Related]

  • 16. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells.
    Wu C, Kim PY, Swystun LL, Liaw PC, Weitz JI.
    J Thromb Haemost; 2016 Feb 13; 14(2):366-74. PubMed ID: 26663133
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.